000281351 001__ 281351
000281351 005__ 20251012002029.0
000281351 0247_ $$2doi$$a10.1111/febs.70011
000281351 0247_ $$2pmid$$apmid:39996490
000281351 0247_ $$2pmc$$apmc:PMC12443472
000281351 0247_ $$2ISSN$$a0014-2956
000281351 0247_ $$2ISSN$$a0945-5795
000281351 0247_ $$2ISSN$$a1432-1033
000281351 0247_ $$2ISSN$$a1742-464X
000281351 0247_ $$2ISSN$$a1742-4658
000281351 0247_ $$2altmetric$$aaltmetric:174549205
000281351 037__ $$aDZNE-2025-01098
000281351 041__ $$aEnglish
000281351 082__ $$a610
000281351 1001_ $$00000-0002-1094-8773$$aFlores-León, Manuel$$b0
000281351 245__ $$aExpanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy.
000281351 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000281351 3367_ $$2DRIVER$$aarticle
000281351 3367_ $$2DataCite$$aOutput Types/Journal article
000281351 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759825735_17317$$xReview Article
000281351 3367_ $$2BibTeX$$aARTICLE
000281351 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281351 3367_ $$00$$2EndNote$$aJournal Article
000281351 520__ $$aA possible consequence of the process of protein aggregation in neurodegenerative diseases is the depletion of soluble protein species (proteinopenia), which may, at least in some cases, reduce protein function/activity. This concept, which is often overlooked, may play a role in synucleinopathies such as Parkinson's disease (PD), and dementia with Lewy bodies (DLB), where the protein α-synuclein (aSyn) is known to accumulate in insoluble inclusions. aSyn is at the crossroads between cellular proteostasis and lipidostasis networks and, therefore, we must be aware of the complexity we face when we try to understand the molecular basis of synucleinopathies. Importantly, aSyn and β-glucocerebrosidase (GCase), a sphingolipid hydrolase also strongly implicated in PD and DLB, are connected to lipid biology and to protein quality control function. Thus, changes in the normal relationship between these two proteins may shift the balance in the cell and lead to proteinopathy and/or proteinopenia, while also affecting lipidostasis of cells in the brain. Thus, pathological mechanisms that are a consequence of (a) loss-of-function, (b) gain-of-toxic function, and (c) alterations in lipidostasis need to be carefully analyzed and integrated in our study of the molecular underpinnings of neurodegenerative mechanisms. Here, we highlight implications of the depletion of the soluble form of aSyn, and of GCase, and discuss how state-of-the-art 'omics technologies' could be deployed to assist in the clinical assessment of synucleinopathies.
000281351 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000281351 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281351 650_7 $$2Other$$aParkinson's disease
000281351 650_7 $$2Other$$aalpha‐synuclein
000281351 650_7 $$2Other$$alipids
000281351 650_7 $$2Other$$aprotein aggregation
000281351 650_7 $$2Other$$asynucleinopathy
000281351 650_7 $$2Other$$atranscription
000281351 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000281351 650_7 $$0EC 3.2.1.45$$2NLM Chemicals$$aGlucosylceramidase
000281351 650_2 $$2MeSH$$aHumans
000281351 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000281351 650_2 $$2MeSH$$aalpha-Synuclein: genetics
000281351 650_2 $$2MeSH$$aSynucleinopathies: metabolism
000281351 650_2 $$2MeSH$$aSynucleinopathies: pathology
000281351 650_2 $$2MeSH$$aSynucleinopathies: genetics
000281351 650_2 $$2MeSH$$aParkinson Disease: metabolism
000281351 650_2 $$2MeSH$$aParkinson Disease: pathology
000281351 650_2 $$2MeSH$$aParkinson Disease: genetics
000281351 650_2 $$2MeSH$$aGlucosylceramidase: genetics
000281351 650_2 $$2MeSH$$aGlucosylceramidase: metabolism
000281351 650_2 $$2MeSH$$aLipid Metabolism
000281351 650_2 $$2MeSH$$aAnimals
000281351 650_2 $$2MeSH$$aProteostasis: genetics
000281351 650_2 $$2MeSH$$aLewy Body Disease: metabolism
000281351 650_2 $$2MeSH$$aLewy Body Disease: pathology
000281351 650_2 $$2MeSH$$aLewy Body Disease: genetics
000281351 7001_ $$0P:(DE-2719)2814138$$aOuteiro, Tiago F$$b1$$eLast author
000281351 773__ $$0PERI:(DE-600)2172518-4$$a10.1111/febs.70011$$gVol. 292, no. 18, p. 4774 - 4788$$n18$$p4774 - 4788$$tThe FEBS journal$$v292$$x0014-2956$$y2025
000281351 8564_ $$uhttps://pub.dzne.de/record/281351/files/DZNE-2025-01098.pdf$$yOpenAccess
000281351 8564_ $$uhttps://pub.dzne.de/record/281351/files/DZNE-2025-01098.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281351 909CO $$ooai:pub.dzne.de:281351$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281351 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281351 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000281351 9141_ $$y2025
000281351 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-03$$wger
000281351 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281351 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-03
000281351 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-03
000281351 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281351 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-03
000281351 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000281351 980__ $$ajournal
000281351 980__ $$aVDB
000281351 980__ $$aUNRESTRICTED
000281351 980__ $$aI:(DE-2719)1410002
000281351 9801_ $$aFullTexts